Azhar M. Awan to Humans
This is a "connection" page, showing publications Azhar M. Awan has written about Humans.
Connection Strength
0.042
-
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2034-41.
Score: 0.004
-
Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec; 1(7):541-5.
Score: 0.004
-
Recent advances in radiation therapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug; 5(4):635-55.
Score: 0.003
-
Palliative radiotherapy. Hematol Oncol Clin North Am. 1990 Dec; 4(6):1169-81.
Score: 0.003
-
Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004 Aug; 45(8):1315-22.
Score: 0.002
-
Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy. Clin Prostate Cancer. 2004 Jun; 3(1):43-8.
Score: 0.002
-
Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med. 2004 Apr; 45(4):571-8.
Score: 0.002
-
Evolution of toxicity after conformal radiotherapy for prostate cancer. Prostate Cancer Prostatic Dis. 2002; 5(4):296-303.
Score: 0.002
-
Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001 Dec 20; 96(6):363-71.
Score: 0.002
-
Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61.
Score: 0.002
-
Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial. Int J Cancer. 2000 Oct 20; 90(5):302-4.
Score: 0.002
-
PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology. 1999 Oct; 54(4):700-5.
Score: 0.001
-
Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am. 1999 Jul-Aug; 5(4):230-6.
Score: 0.001
-
Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Feb 01; 37(3):551-7.
Score: 0.001
-
Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):977-85.
Score: 0.001
-
Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys. 1993 Jul 15; 26(4):721-9.
Score: 0.001
-
Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J Urol. 1993 Apr; 149(4):753-7.
Score: 0.001
-
Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993 Jan 15; 25(2):359-71.
Score: 0.001
-
Beams eye view-based photon radiotherapy I. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1575-86.
Score: 0.001
-
Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug; 5(4):753-67.
Score: 0.001
-
Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys. 1991 Mar; 20(3):413-7.
Score: 0.001
-
Radiobiological characterization of head and neck and sarcoma cells derived from patients prior to radiotherapy. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):313-9.
Score: 0.001
-
Breast conserving surgery and definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1211-6.
Score: 0.001
-
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
Score: 0.001
-
In vitro radiobiological parameters of human sarcoma cell lines. Int J Radiat Oncol Biol Phys. 1988 Oct; 15(4):937-42.
Score: 0.001
-
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8.
Score: 0.001
-
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
Score: 0.001